United StatesAmoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5 mL, 100 mL when reconstituted (NDC 0093-2277-7), Lot #100062316, Exp 01/2026, manufactured by Teva Canada Limited for Teva Pharmaceuticals USA, Inc. is being recalled. It was recalled because the clavulanate potassium component is subpotent; 4,680 cartons were distributed in Mississippi, Ohio, and California.
What's being recalled
Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
Recalling firm: Teva Pharmaceuticals USA, Inc, Parsippany, NJ, United States.
How to identify it
Lot # 100062316, Exp Date: 01/2026
The hazard
Subpotent drug; Clavulanate Potassium component
What to do
Don't stop taking a prescribed medicine without talking to your doctor or pharmacist first. For other products, stop using them and ask the pharmacist, seller or maker what to do.
The notice doesn't give instructions for consumers, so this is general advice for health & beauty recalls. Check the official notice for the details.
Where it was sold
Distributed in three (3) States: MS, OH, CA.
The official notice
This page is a summary of the notice published by U.S. Food and Drug Administration (enforcement reports), collected from U.S. Food and Drug Administration (enforcement reports). Check the original before you act on it.
Read the official notice (opens in a new tab)